Skip to main content
Top
Published in: BMC Medicine 1/2016

Open Access 01-12-2016 | Research article

The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance

Authors: Florian Gehre, Jacob Otu, Lindsay Kendall, Audrey Forson, Awewura Kwara, Samuel Kudzawu, Aderemi O. Kehinde, Oludele Adebiyi, Kayode Salako, Ignatius Baldeh, Aisha Jallow, Mamadou Jallow, Anoumou Dagnra, Kodjo Dissé, Essosimna A. Kadanga, Emmanuel Oni Idigbe, Catherine Onubogu, Nneka Onyejepu, Aissatou Gaye-Diallo, Awa Ba-Diallo, Paulo Rabna, Morto Mane, Moumine Sanogo, Bassirou Diarra, Zingue Dezemon, Adama Sanou, Madikay Senghore, Brenda A. Kwambana-Adams, Edward Demba, Tutty Faal-Jawara, Samrat Kumar, Leopold D. Tientcheu, Adama Jallow, Samba Ceesay, Ifedayo Adetifa, Assan Jaye, Mark J. Pallen, Umberto D’Alessandro, Beate Kampmann, Richard A. Adegbola, Souleymane Mboup, Tumani Corrah, Bouke C. de Jong, Martin Antonio

Published in: BMC Medicine | Issue 1/2016

Login to get access

Abstract

Background

Drug-resistant tuberculosis (TB) is a global public health problem. Adequate management requires baseline drug-resistance prevalence data. In West Africa, due to a poor laboratory infrastructure and inadequate capacity, such data are scarce. Therefore, the true extent of drug-resistant TB was hitherto undetermined. In 2008, a new research network, the West African Network of Excellence for Tuberculosis, AIDS and Malaria (WANETAM), was founded, comprising nine study sites from eight West African countries (Burkina Faso, The Gambia, Ghana, Guinea-Bissau, Mali, Nigeria, Senegal and Togo). The goal was to establish Good Clinical Laboratory Practice (GCLP) principles and build capacity in standardised smear microscopy and mycobacterial culture across partnering laboratories to generate the first comprehensive West African drug-resistance data.

Methods

Following GCLP and laboratory training sessions, TB isolates were collected at sentinel referral sites between 2009–2013 and tested for first- and second-line drug resistance.

Results

From the analysis of 974 isolates, an unexpectedly high prevalence of multi-drug-resistant (MDR) strains was found in new (6 %) and retreatment patients (35 %) across all sentinel sites, with the highest prevalence amongst retreatment patients in Bamako, Mali (59 %) and the two Nigerian sites in Ibadan and Lagos (39 % and 66 %). In Lagos, MDR is already spreading actively amongst 32 % of new patients. Pre-extensively drug-resistant (pre-XDR) isolates are present in all sites, with Ghana showing the highest proportion (35 % of MDR). In Ghana and Togo, pre-XDR isolates are circulating amongst new patients.

Conclusions

West African drug-resistance prevalence poses a previously underestimated, yet serious public health threat, and our estimates obtained differ significantly from previous World Health Organisation (WHO) estimates. Therefore, our data are reshaping current concepts and are essential in informing WHO and public health strategists to implement urgently needed surveillance and control interventions in West Africa.
Literature
1.
go back to reference Roca A, Afolabi MO, Saidu Y, Kampmann B. Ebola: a holistic approach is required to achieve effective management and control. J Allergy Clin Immunol. 2015;135:856–67.CrossRefPubMedPubMedCentral Roca A, Afolabi MO, Saidu Y, Kampmann B. Ebola: a holistic approach is required to achieve effective management and control. J Allergy Clin Immunol. 2015;135:856–67.CrossRefPubMedPubMedCentral
2.
go back to reference Miiro GM, Oukem-Boyer OO, Sarr O, Rahmani M, Ntoumi F, et al. EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. BMC Public Health. 2013;13:258.CrossRefPubMedPubMedCentral Miiro GM, Oukem-Boyer OO, Sarr O, Rahmani M, Ntoumi F, et al. EDCTP regional networks of excellence: initial merits for planned clinical trials in Africa. BMC Public Health. 2013;13:258.CrossRefPubMedPubMedCentral
3.
go back to reference World Health Organization. WHO report, global tuberculosis report. Geneva: World Health Organization; 2014. World Health Organization. WHO report, global tuberculosis report. Geneva: World Health Organization; 2014.
4.
go back to reference World Health Organization. Multidrug-resistant tuberculosis (MDR-TB), 2014 update. Geneva: World Health Organization; 2014. World Health Organization. Multidrug-resistant tuberculosis (MDR-TB), 2014 update. Geneva: World Health Organization; 2014.
5.
go back to reference International Air Transport Association. Infectious substances shipping guidelines — The complete reference guide for pharmaceutical & health professionals. 12th ed. Montreal: IATA; 2013. International Air Transport Association. Infectious substances shipping guidelines — The complete reference guide for pharmaceutical & health professionals. 12th ed. Montreal: IATA; 2013.
6.
go back to reference Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2001;39:4440–4.CrossRefPubMedPubMedCentral Ardito F, Posteraro B, Sanguinetti M, Zanetti S, Fadda G. Evaluation of BACTEC Mycobacteria Growth Indicator Tube (MGIT 960) automated system for drug susceptibility testing of Mycobacterium tuberculosis. J Clin Microbiol. 2001;39:4440–4.CrossRefPubMedPubMedCentral
7.
go back to reference World Health Organization. The Stop TB Department. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization; 2008. World Health Organization. The Stop TB Department. Policy guidance on drug-susceptibility testing (DST) of second-line antituberculosis drugs. Geneva: World Health Organization; 2008.
8.
go back to reference Ani AE, Idoko J, Dalyop YB, Pitmang SL. Drug resistance profile of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Jos, Nigeria. Trans R Soc Trop Med Hyg. 2009;103:67–71.CrossRefPubMed Ani AE, Idoko J, Dalyop YB, Pitmang SL. Drug resistance profile of Mycobacterium tuberculosis isolates from pulmonary tuberculosis patients in Jos, Nigeria. Trans R Soc Trop Med Hyg. 2009;103:67–71.CrossRefPubMed
9.
go back to reference Daniel O, Osman E. Prevalence and risk factors associated with drug resistant TB in South West, Nigeria. Asian Pac J Trop Med. 2011;4:148–51.CrossRefPubMed Daniel O, Osman E. Prevalence and risk factors associated with drug resistant TB in South West, Nigeria. Asian Pac J Trop Med. 2011;4:148–51.CrossRefPubMed
10.
go back to reference Kehinde AO, Adebiyi EO. Molecular diagnosis of MDR-TB using GenoType MTBDRplus 96 assay in Ibadan, Nigeria. Niger J Physiol Sci. 2013;28:187–91.PubMed Kehinde AO, Adebiyi EO. Molecular diagnosis of MDR-TB using GenoType MTBDRplus 96 assay in Ibadan, Nigeria. Niger J Physiol Sci. 2013;28:187–91.PubMed
11.
go back to reference Lawson L, Yassin MA, Abdurrahman ST, Parry CM, Dacombe R, et al. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Trop Med Int Health. 2011;16:974–80.CrossRefPubMed Lawson L, Yassin MA, Abdurrahman ST, Parry CM, Dacombe R, et al. Resistance to first-line tuberculosis drugs in three cities of Nigeria. Trop Med Int Health. 2011;16:974–80.CrossRefPubMed
12.
go back to reference Otu A, Umoh V, Habib A, Ansa V. Prevalence and clinical predictors of drug-resistant tuberculosis in three clinical settings in Calabar, Nigeria. Clin Respir J. 2014;8:234–9.CrossRefPubMed Otu A, Umoh V, Habib A, Ansa V. Prevalence and clinical predictors of drug-resistant tuberculosis in three clinical settings in Calabar, Nigeria. Clin Respir J. 2014;8:234–9.CrossRefPubMed
13.
go back to reference Sangare L, Diande S, Badoum G, Dingtoumda B, Traore AS. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int J Tuberc Lung Dis. 2010;14:1424–9.PubMed Sangare L, Diande S, Badoum G, Dingtoumda B, Traore AS. Anti-tuberculosis drug resistance in new and previously treated pulmonary tuberculosis cases in Burkina Faso. Int J Tuberc Lung Dis. 2010;14:1424–9.PubMed
14.
go back to reference Sangare L, Diande S, Kouanda S, Dingtoumda BI, Mourfou A, et al. Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso. Ann Afr Med. 2010;9:15–9.CrossRefPubMed Sangare L, Diande S, Kouanda S, Dingtoumda BI, Mourfou A, et al. Mycobacterium tuberculosis drug-resistance in previously treated patients in Ouagadougou, Burkina Faso. Ann Afr Med. 2010;9:15–9.CrossRefPubMed
15.
go back to reference Saleri N, Badoum G, Ouedraogo M, Dembele SM, Nacanabo R, et al. Extensively drug-resistant tuberculosis, Burkina Faso. Emerg Infect Dis. 2010;16:840–2.CrossRefPubMedPubMedCentral Saleri N, Badoum G, Ouedraogo M, Dembele SM, Nacanabo R, et al. Extensively drug-resistant tuberculosis, Burkina Faso. Emerg Infect Dis. 2010;16:840–2.CrossRefPubMedPubMedCentral
16.
go back to reference Sebastian V. From facility to finding drug resistance mutations: drug resistance survey in Nigeria. 45th Union World Conference on Lung Health. Barcelona; 2014. p. 57. Sebastian V. From facility to finding drug resistance mutations: drug resistance survey in Nigeria. 45th Union World Conference on Lung Health. Barcelona; 2014. p. 57.
17.
go back to reference Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, et al. Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis. 2003;7:390–3.PubMed Adegbola RA, Hill P, Baldeh I, Otu J, Sarr R, et al. Surveillance of drug-resistant Mycobacterium tuberculosis in The Gambia. Int J Tuberc Lung Dis. 2003;7:390–3.PubMed
18.
go back to reference Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684–92.CrossRefPubMed Van Deun A, Maug AK, Salim MA, Das PK, Sarker MR, et al. Short, highly effective, and inexpensive standardized treatment of multidrug-resistant tuberculosis. Am J Respir Crit Care Med. 2010;182:684–92.CrossRefPubMed
19.
go back to reference Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19:517–24.CrossRefPubMed Kuaban C, Noeske J, Rieder HL, Ait-Khaled N, Abena Foe JL, et al. High effectiveness of a 12-month regimen for MDR-TB patients in Cameroon. Int J Tuberc Lung Dis. 2015;19:517–24.CrossRefPubMed
20.
go back to reference Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18:1188–94.CrossRefPubMed Piubello A, Harouna SH, Souleymane MB, Boukary I, Morou S, et al. High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses. Int J Tuberc Lung Dis. 2014;18:1188–94.CrossRefPubMed
Metadata
Title
The emerging threat of pre-extensively drug-resistant tuberculosis in West Africa: preparing for large-scale tuberculosis research and drug resistance surveillance
Authors
Florian Gehre
Jacob Otu
Lindsay Kendall
Audrey Forson
Awewura Kwara
Samuel Kudzawu
Aderemi O. Kehinde
Oludele Adebiyi
Kayode Salako
Ignatius Baldeh
Aisha Jallow
Mamadou Jallow
Anoumou Dagnra
Kodjo Dissé
Essosimna A. Kadanga
Emmanuel Oni Idigbe
Catherine Onubogu
Nneka Onyejepu
Aissatou Gaye-Diallo
Awa Ba-Diallo
Paulo Rabna
Morto Mane
Moumine Sanogo
Bassirou Diarra
Zingue Dezemon
Adama Sanou
Madikay Senghore
Brenda A. Kwambana-Adams
Edward Demba
Tutty Faal-Jawara
Samrat Kumar
Leopold D. Tientcheu
Adama Jallow
Samba Ceesay
Ifedayo Adetifa
Assan Jaye
Mark J. Pallen
Umberto D’Alessandro
Beate Kampmann
Richard A. Adegbola
Souleymane Mboup
Tumani Corrah
Bouke C. de Jong
Martin Antonio
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Medicine / Issue 1/2016
Electronic ISSN: 1741-7015
DOI
https://doi.org/10.1186/s12916-016-0704-5

Other articles of this Issue 1/2016

BMC Medicine 1/2016 Go to the issue